CRKL oncogene is downregulated by p53 through miR-200s

Cancer Science

Volumn 106, Issue 8, 2015, Pages 1033-1040

  Tamura, Miyuki ^a   Sasaki, Yasushi ^a   Kobashi, Kenta ^a   Takeda, Kousuke ^a   Nakagaki, Takafumi ^a   Idogawa, Masashi ^a   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

CRKL; Cell growth; MiR 200 family; P53; P53 family

Indexed keywords

MESSENGER RNA; MICRORNA 141; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 429; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CRK LIKE PROTEIN; MICRORNA; MIRN200 MICRORNA, HUMAN; MIRN429 MICRORNA, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; A549 CELL LINE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 12; COMPUTER MODEL; CONTROLLED STUDY; CRKL GENE; DNA RESPONSIVE ELEMENT; GENE; GENE CLUSTER; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TP53 GENE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939213173     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12713     Document Type: Article

References (47)

1. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 2004; 95: 7-11.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
3. Feng Z, Zhang C, Wu R et al. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011; 3: 44-50.
4. Bommer GT, Gerin I, Feng Y et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-307.
5. He L, He X, Lim LP et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130-4.
6. Tazawa H, Tsuchiya N, Izumiya M et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472-7.
7. Georges SA, Biery MC, Kim SY et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 2008; 68: 10105-12.
8. Song B, Wang Y, Kudo K et al. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res 2008; 14: 8080-6.
9. Christoffersen NR, Shalgi R, Frankel LB et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010; 17: 236-45.
10. Sachdeva M, Zhu S, Wu F et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207-12.
11. Pichiorri F, Suh SS, Rocci A et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367-81.
12. Zhang J, Sun Q, Zhang Z et al. Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 2013; 32: 61-9.
13. Shimono Y, Zabala M, Cho RW et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
14. Wellner U, Schubert J, Burk UC et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-95.
15. Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene 2001; 20: 6348-71.
16. Han B, Luan L, Xu Z et al. Clinical significance and biological roles of CRKL in human bladder carcinoma. Tumour Biol 2013; 35: 4101-6.
17. Lin F, Chengyao X, Qingchang L et al. CRKL promotes lung cancer cell invasion through ERK-MMP9 pathway. Mol Carcinog 2014; S1: E35-44.
18. Natsume H, Shinmura K, Tao H et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med 2012; 10: 97.
19. Zhao T, Miao Z, Wang Z et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol 2013; 34: 2891-7.
20. Kim YH, Kwei KA, Girard L et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 2010; 29: 1421-30.
21. Fomenkov A, Zangen R, Huang YP et al. RACK1 and stratifin target DeltaNp63alpha for a proteasome degradation in head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 2004; 3: 1285-95.
22. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007; 7: 165-8.
23. Wu N, Rollin J, Masse I et al. p63 regulates human keratinocyte proliferation via MYC-regulated gene network and differentiation commitment through cell adhesion-related gene network. J Biol Chem 2012; 287: 5627-38.
24. Idogawa M, Ohashi T, Sasaki Y et al. Identification and analysis of large intergenic non-coding RNAs regulated by p53 family members through a genome-wide analysis of p53-binding sites. Hum Mol Genet 2014; 23: 2847-57.
25. Chang CJ, Chao CH, Xia W et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-23.
26. Kim T, Veronese A, Pichiorri F et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875-83.
27. Knouf EC, Garg K, Arroyo JD et al. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 2012; 40: 499-510.
28. John B, Enright AJ, Aravin A et al. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
29. Krek A, Grun D, Poy MN et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
30. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
31. Sasaki Y, Negishi H, Idogawa M et al. p53 negatively regulates the hepatoma growth factor HDGF. Cancer Res 2011; 71: 7038-47.
32. Mizuno H, Kitada K, Nakai K et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2009; 2: 18.
33. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003; 10: 404-8.
34. Tamura M, Sasaki Y, Koyama R et al. Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness. Oncogene 2014; 33: 4837-46.
35. Birge RB, Kalodimos C, Inagaki F et al. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal 2009; 7: 13.
36. Prosser S, Sorokina E, Pratt P et al. CrkIII: a novel and biologically distinct member of the Crk family of adaptor proteins. Oncogene 2003; 22: 4799-806.
37. Mayer BJ, Hamaguchi M, Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature 1988; 332: 272-5.
38. Liu CH, Chen TC, Chau GY et al. Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. Mol Cell Proteomics 2013; 12: 1335-49.
39. Wang Y, Dong QZ, Fu L et al. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog 2013; 52: 890-9.
40. Cheung HW, Du J, Boehm JS et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011; 1: 608-25.
41. Cheng S, Guo J, Yang Q et al. Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas. Med Oncol 2015; 32: 47.
42. Feng R, Chen X, Yu Y et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010; 298: 50-63.
43. Hamada S, Satoh K, Fujibuchi W et al. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 2012; 10: 3-10.
44. Tavazoie SF, Alarcon C, Oskarsson T et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-52.
45. Wang J, Chen X, Li P et al. CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. Chem Biol Interact 2013; 206: 230-8.
46. Kardinal C, Konkol B, Schulz A et al. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J 2000; 14: 1529-38.
47. Savitski MM, Reinhard FB, Franken H et al. Proteomics. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 2014; 346: 1255784.